The 2-day meeting of the American Cough Conference will cover new developments in the treatment of cough, as well as insights into the mechanisms and management of cough, said Peter Dicpinigaitis, MD, chair of the American Cough Conference.
The 2-day meeting of the American Cough Conference will cover new developments in the treatment of cough, as well as insights into the mechanisms and management of cough, said Peter Dicpinigaitis, MD, chair of the American Cough Conference, professor of medicine at the Albert Einstein College of Medicine, director of the Montefiore Cough Center, and editor-in-chief of LUNG.
What presentations or sessions are you looking forward to most this year at the American Cough Conference?
So, as a bit of background, the American Cough Conference [ACC] is a biannual conference that we started back in 2007. So, next week's meeting will be, in fact, our eighth American Cough Conference. And what the ACC is, is a 2-day conference with a faculty of really many or most of the world's cough experts, and an audience of people that have an interest in cough, either as clinicians, pharmacists, basic scientists, etc. So, it's a very enjoyable meeting. Unfortunately, we'll be virtual this year, and hopefully back to in person at our next meeting in June 2023.
So as usual, we spend our 2 days really covering all of the new developments in cough in terms of treatment mechanisms, insights, new therapies. So, specifically, some of the presentations we have at this year's meeting is an update on the recently published adult and pediatric cough management guidelines, which will be reviewed by experts and coauthors of those guidelines. We’ll have talks about clinical trial design and the placebo effect in cough studies, which has been a major issue if you look at the literature on cough. We, of course, have new insights into the mechanisms and management of cough for us clinicians in the audience. And oftentimes, the most exciting part of the conference is looking at new antitussive drugs in the pipeline.